Lior M. Hirsch, Larry E. Goldstein

Canadian Journal of Urology, Vol.22, No.4, pp. 7938-7941, 2015

Abstract In men with advanced carcinoma of the prostate being treated with androgen deprivation therapy (ADT), hot flashes can be a significant side effect of the treatment. In this paper we describe using acupuncture as a complementary alternative therapy for treatment of hot flashes in men. More >

Vladimir Ruzhynsky, Paul Whelan

Canadian Journal of Urology, Vol.20, No.3, pp. 6808-6810, 2013

Abstract Gonadotropin releasing hormone (GnRH) antagonists, such as degarelix, are emerging as an androgen deprivation therapy primary agents in a treatment of advanced prostate cancer. The role of GnRH antagonists in management of lower urinary tract symptoms associated with prostate cancer has not been clearly established. In this report, we describe the case of a patient with locally advanced prostate cancer who presented with symptoms of urinary retention and renal failure. The use of degarelix in this patient led to a rapid reduction in the prostate-specific antigen level; however, obstructive symptoms persisted despite the use of More >

Bradley C. Carthon^1,2, David M. Marcus^2,3, Lindsey A. Herrel⁴, Ashesh B. Jani^2,3,4, Peter J. Rossi^2,3,4, Daniel J. Canter^2,4

Canadian Journal of Urology, Vol.20, No.3, pp. 6748-6755, 2013

Abstract Introduction: Radical prostatectomy is an effective primary treatment for clinically localized prostate cancer. While many patients are cured of their disease after surgery, there are still a significant proportion of men who will develop a biochemical recurrence (BCR). In this review, we detail existing treatment algorithms for this group of patients as well as future therapies that show great promise.
Materials and methods: A review of the literature was performed, and relevant, high-impact articles were identified and reviewed focusing on the treatment of men with BCR after surgery for prostate cancer. Wherever possible, we used data from… More >

Daniel M. Bernad¹, Alan Dal Pra¹, Cintia Baule¹, Benicio N. Frey², Sergio Faria¹

Canadian Journal of Urology, Vol.20, No.4, pp. 6868-6870, 2013

Abstract Androgen deprivation therapy (ADT) is commonly used in the treatment of prostate cancer and is associated with several side effects including psychiatric disorders. We present an unusual case of a 62-year-old man with high risk prostate cancer that developed de novo psychosis after starting luteinizing hormone-releasing hormone (LHRH) agonists and discuss possible mechanisms to explain such fndings. This case report highlights the importance of continuing assessment and monitoring of potential emotional and behavioral symptoms in prostate cancer patients treated with ADT. More >

Siddhartha Baxi, Charles Catton

Canadian Journal of Urology, Vol.17, No.6, pp. 5436-5441, 2010

Abstract Introduction: Level 1 evidence demonstrates the benefit of postoperative radiotherapy (PORT) for pT3 disease and positive margins. The role of androgen deprivation therapy (ADT) after PORT remains to be defined from results of ongoing randomized trials. This study was undertaken to determine the factors influencing the current use of ADT after PORT amongst Canadian radiation oncologists.
Methods: An institutional survey was emailed to the Genito-urinary Radiation Oncologists Group of Canada (GUROC), designed to assess the likelihood of prescribing ADT in early and delayed PORT scenarios with variations in disease prognosticators. Analysis used descriptive statistics.
Results: Majority (94%) do… More >

Mohamed A. Elshaikh¹, Willie Underwood², Daniel E. Soto¹

Canadian Journal of Urology, Vol.16, No.1, pp. 4495-4497, 2009

Abstract We report a case history of a patient with Parkinson’s disease (PD) treated with androgen deprivation therapy (ADT) and external beam radiation for prostate cancer, who developed severe deterioration of his PD during ADT. More >

Yiu-Keung Lau^1,2, C. Ellen Lee³, Heather J. Prior⁴, Lisa M. Lix⁵, Colleen J. Metge⁶, William D. Leslie⁷

Canadian Journal of Urology, Vol.16, No.6, pp. 4908-4914, 2009

Abstract Introduction: Prostate cancer is the most common noncutaneous malignancy diagnosed in men. The use of androgen deprivation therapy (ADT) is the mainstay of treatment for metastatic disease. The use of ADT has been reported to increase the risk of osteoporosis in men with prostate cancer, with higher risk of fracture than age matched controls. We sought to confirm the higher fracture risk of men with prostate cancer on ADT in the Canadian population.
Methods: We used the Population Health Research Data Repository housed at Manitoba Centre for Health Policy to identify all cases of fractures of the… More >

Alvaro Morales

Canadian Journal of Urology, Vol.15, No.5, pp. 4256-4256, 2008

Abstract This article has no abstract. More >

Christopher J. DiBlasio¹, Jessica Hammett¹, John B. Malcolm¹, Beth A. Judge², Jamie H. Womack², Matthew C. Kincade¹, Mitchell L. Ogles¹, John M. Mancini¹, Anthony L. Patterson¹, Robert W. Wake¹, Ithaar H. Derweesh¹

Canadian Journal of Urology, Vol.15, No.5, pp. 4249-4256, 2008

Abstract Objective: Androgen deprivation therapy (ADT) remains a widely utilized modality for treatment of localized and advanced prostate cancer. While ADT-induced alterations in testosterone have demonstrated impacts on quality of life, the effects on mental health remain ill-defined. We investigated the prevalence of de novo psychiatric illness and predictive factors following ADT induction for prostate cancer.
Materials and methods: We retrospectively reviewed patients receiving ADT for prostate cancer at our institution between 1/1989-7/2005, excluding men receiving only neoadjuvant ADT. Variables included age, race, body mass index, prostate-specific antigen (PSA), Gleason sum, clinical stage, ADT type (medical/surgical) and schedule… More >

Eric A. Singer, Dragan J. Golijanin, Edward M. Messing

Canadian Journal of Urology, Vol.15, No.6, pp. 4381-4387, 2008

Abstract Androgen deprivation therapy (ADT) has been the cornerstone of treatment for advanced prostate cancer for over 65 years. Although there can be worrisome side effects, data will be presented that for men with metastatic prostate cancer, immediate ADT can reduce the likelihood of developing the rare but catastrophic sequellae of metastatic disease, although it is unlikely to prolong survival compared with waiting for symptoms before initiating ADT. Additionally, for patients with extremely high risk prostate cancer that is not distantly metastatic (e.g. have a life expectancy from prostate cancer less than 10 years with all… More >